Published in Ann Neurol on June 01, 1992
Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain (2011) 1.50
Sympathetic modulation of immunity: relevance to disease. Cell Immunol (2008) 1.33
Whole-body tissue stabilization and selective extractions via tissue-hydrogel hybrids for high-resolution intact circuit mapping and phenotyping. Nat Protoc (2015) 1.25
Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions. Proc Natl Acad Sci U S A (1993) 0.97
G protein-coupled receptors as therapeutic targets for multiple sclerosis. Cell Res (2012) 0.90
Neuroendocrine immunoregulation in multiple sclerosis. Clin Dev Immunol (2013) 0.87
Extracting structural and functional features of widely distributed biological circuits with single cell resolution via tissue clearing and delivery vectors. Curr Opin Biotechnol (2016) 0.86
Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases. Ann Rheum Dis (2001) 0.80
Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications. Curr Neuropharmacol (2014) 0.78
Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol Neurosurg Psychiatry (2003) 0.76
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75
Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain (2003) 3.65
Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain (2003) 3.04
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med (1995) 2.28
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol (2000) 2.13
Distinct calcium channels are generated by alternative splicing and are differentially expressed in the mammalian CNS. Neuron (1991) 2.06
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
The Functional Independence Measure: a comparative validity and reliability study. Disabil Rehabil (1995) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Immunologic studies in IgA nephropathy. Kidney Int (1980) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97
Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci U S A (1992) 1.88
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol (1998) 1.86
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol (1997) 1.73
Rat brain expresses a heterogeneous family of calcium channels. Proc Natl Acad Sci U S A (1990) 1.73
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Community services in multiple sclerosis: still a matter of chance. J Neurol Neurosurg Psychiatry (2000) 1.68
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Evidence-based measurement: which disability scale for neurologic rehabilitation? Neurology (2001) 1.66
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry (2002) 1.64
Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J Neuroimmunol (1991) 1.63
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol (2003) 1.59
Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology (2001) 1.58
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology (1999) 1.58
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain (2007) 1.55
Control of abscisic acid synthesis. J Exp Bot (2000) 1.55
Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure. J Neurol Neurosurg Psychiatry (1999) 1.54
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry (1999) 1.53
Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain (2006) 1.53
A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain (1994) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain (1995) 1.53
Diffusion tractography based group mapping of major white-matter pathways in the human brain. Neuroimage (2003) 1.51
Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci (1987) 1.50
Altered middle lamella homogalacturonan and disrupted deposition of (1-->5)-alpha-L-arabinan in the pericarp of Cnr, a ripening mutant of tomato. Plant Physiol (2001) 1.50
From diffusion tractography to quantitative white matter tract measures: a reproducibility study. Neuroimage (2003) 1.49
Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. Health Technol Assess (2004) 1.49
IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol (1977) 1.49
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology (1990) 1.47
Painful extremities and neurological disorder in essential thrombocythaemia. J R Soc Med (1984) 1.44
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci (1994) 1.43
The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain (2000) 1.41
Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol (2003) 1.41
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current. Mol Pharmacol (2001) 1.40
The lipid composition of rat brain myelin and subcellular fractions during development. Biochem J (1968) 1.39
Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine (1993) 1.37
The chemical composition of vertebrate myelin and microsomes. J Neurochem (1965) 1.37
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia (2008) 1.36
Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol (1994) 1.35
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology (2004) 1.34
Ca channels induced in Xenopus oocytes by rat brain mRNA. J Neurosci (1987) 1.34
The correlation of coronary angiography and the electrocardiographic response to maximal treadmill testing in 76 asymptomatic men. Circulation (1973) 1.34
A clinical and laboratory study of benign multiple sclerosis. Q J Med (1986) 1.31
Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J Neurol Neurosurg Psychiatry (1988) 1.31
Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 1.30
T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J Exp Med (1992) 1.30
EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.29
Evidence for the involvement of more than one mRNA species in controlling the inactivation process of rat and rabbit brain Na channels expressed in Xenopus oocytes. J Neurosci (1988) 1.29
A beta-subunit normalizes the electrophysiological properties of a cloned N-type Ca2+ channel alpha 1-subunit. Neuropharmacology (1993) 1.29
The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain (2001) 1.29
Spinal cord atrophy and disability in MS: a longitudinal study. Neurology (1998) 1.28
Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry (1996) 1.28
Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 1.27
Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain (1991) 1.26
Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology (1996) 1.25
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol (2008) 1.25
Serial magnetization transfer imaging in acute optic neuritis. Brain (2004) 1.24
Quantitative thin layer chromatography of lipids. J Chromatogr (1967) 1.24
Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol (2003) 1.22
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain (1999) 1.22
High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry (1992) 1.21
Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology (2005) 1.20
Sarcoidosis presenting with stroke. Stroke (1989) 1.20
Protein kinase C-mediated enhancement of NMDA currents by metabotropic glutamate receptors in Xenopus oocytes. J Physiol (1992) 1.20
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology (1995) 1.19